Phase 2Completed

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

A Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Tranilast in Combination With Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

Sponsor
Nuon Therapeutics, Inc. (Industry)
Enrollment
112 enrolled
Conditions
Moderate to Severe Gout; Hyperuricemia
Interventions
Combination 400; Allopurinol; Combination 600
Ages
adults, older adults
Registry
NCT01109121

Full record on ClinicalTrials.gov

From the registry

This Phase 2 study will be a multicenter, double-blind, randomized, active-comparator study to evaluate the safety and efficacy of tranilast in combination with allopurinol in patients with hyperuricemia and moderate to severe gout.

Primary outcomes

  • Percent change from baseline in serum uric acid (sUA) levels

History

  1. Study completion

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered